Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of CAR (Chimeric Antigen Receptor) Modified Autologous T Cell CCT301-59 in Patients With Recurrent or Refractory Solid Tumors on the Basis of Safety, Tolerability and Anti-tumor Activity Study.

NCT03960060 is registered in ClinicalTrials.gov with Shanghai PerHum Therapeutics Co., Ltd. as lead sponsor.

NCT NCT03960060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03960060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of CAR (Chimeric Antigen Receptor) Modified Autologous T Cell CCT301-59 in Patients With Recurrent or Refractory Solid Tumors on the Basis of Safety, Tolerability and Anti-tumor Activity Study.
Lead sponsor
Shanghai PerHum Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
May 16, 2019
Completion date
June 30, 2023
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, gastric cancer, pancreatic cancer, soft tissue sarcoma, solid tumor